Ian Lloyd
Senior Director, Pharmaprojects & Data Integration
Senior Director, Pharmaprojects & Data Integration
UK
35+ years of experience
His expertise includes identifying and analyzing trends in pharma R&D. For over 20 years, he has authored the “Pharma Annual R&D review” and its new active substances (NAS) launches supplement. This has become a must-have industry report for those seeking to identify the changing fortunes of drug R&D.
Ian joined Pharmaprojects in 1987, when it was part of PJB Publications. It was acquired by Informa in 2003.
He previously worked in molecular biology as a research assistant at the University of Bristol.
Ian Lloyd 17 Jun 2022
Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.
Ian Lloyd 09 Apr 2021
Our world was disrupted at warp speed during 2020. Are you ready to gain a deeper understanding of the year that changed our perceptions of possible?
Ian Lloyd 28 May 2020
Recently, Pharma Intelligence brought you the Pharma R&D Annual Review 2020 Webinar, followed up with the NAS (New Active Substances) Infographic. We now invite you to go even deeper into pharma R&D successes for 2019 with your free copy of the NAS Supplement.
Ian Lloyd 19 May 2020
Don’t miss your view into the NAS that made an impact last year, your follow-up to the Pharma R&D Annual Review 2020 webinar.
Ian Lloyd 15 May 2020
世界の医薬品産業における研究開発トレンドを検証する年次ホワイトペーパー『Pharma R&D Annual Review 2020』が発行されました。1980年以来、弊社が追跡してきた世界の医薬品情報の蓄積を駆使して、会社別、治療領域別、疾病別、標的および剤型別にパイプラインを検証し、業界トレンドを評価しました。
Drug Development Landscape Drug Review Research & Development
Ian Lloyd 15 May 2020
世界の医薬品産業におけるR&Dトレンドを検証するホワイトペーパー『Pharma R&D Annual Review 2020』からポイントをピックアップして、執筆者のイアン・ロイドがオンラインセミナーを行いました（2020年4月28日）。新たな10年の幕開けとともにR&Dはどこへ向かうのでしょうか。Pharmaprojectsのデータ粒度の向上を受けて、今年は新たに様々な分析を実施し、これまで以上に深くパイプラインを掘り下げています。
Ian Lloyd 30 May 2019
Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.
Ian Lloyd 30 May 2019
Pharma R&D Annual Review 2019 is based on the stats and data from from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects.
Clinical Trials Diseases Research & Development Approvals Drug Review
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Ian Lloyd 16 May 2019
オンラインセンナ―：Pharma R&D Review - 2018年に起きた変化と2019年の注目点 （2019年4月17日実施）
Ian Lloyd 12 Mar 2019
Get your head in the game with a free download of the Pharma R&D Annual Review 2019 infographic from Informa Pharma Intelligence. This year’s look at the key players and reigning champs of R&D uses a sports theme to present its critical data on the current state of pharma R&D.
Research & Development Drug Development Landscape Diseases Drug Review
Ian Lloyd 23 May 2018
Keep in tune with the current landscape for pharma R&D with a free, information-packed webinar recording from Informa Pharma Intelligence. In the Global Pharma R&D Review webinar, our experts hit all the right notes as they used a music theme to explore key issues affecting R&D today, and offer a glimpse of what the rest of 2018 may look like.
Ian Lloyd 10 Apr 2018
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects. Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Ian Lloyd 22 Mar 2017
Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.
Ian Lloyd 22 Mar 2017
Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.
Ian Lloyd 02 May 2016
Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. As such, this list represents a subset of all the first launches which Citeline reported during 2015, excluding the 68 new drug launches with reformulated or non-NAS moieties, or biosimilars.
世界の薬事規制動向＆情報を配信
15 Apr 2016
世界の薬事規制動向＆情報を配信
15 Apr 2016
世界の薬事規制動向＆情報を配信
14 Apr 2016
世界の薬事規制動向＆情報を配信
12 Apr 2016
世界の薬事規制動向＆情報を配信
11 Apr 2016
Medtech Insight: 世界の...
11 Apr 2016
Scrip: 世界の医療用医薬品＆製薬産...
07 Apr 2016
世界の薬事規制動向＆情報を配信
07 Apr 2016
世界の薬事規制動向＆情報を配信
05 Apr 2016
Scrip: 世界の医療用医薬品＆製薬産...
05 Apr 2016
世界の薬事規制動向＆情報を配信
05 Apr 2016
世界の薬事規制動向＆情報を配信
04 Apr 2016
Scrip: 世界の医療用医薬品＆製薬産...
04 Apr 2016
Scrip: 世界の医療用医薬品＆製薬産...
01 Apr 2016
世界の薬事規制動向＆情報を配信
31 Mar 2016
